Related Experiment Video

Updated: Mar 25, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

14.0K

[HSP90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/β-Catenin Signaling

Kan-Kan Chen1, Zheng-Mei He1, Bang-He Ding1

  • 1Department of Hematology, Department of Statisties, Huaian First Hospital Affiliated to Nanjing Medical University, Huaian 223300, Jiangsu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|February 26, 2016
PubMed
Abstract

Insights

The heat shock protein 90 (HSP90) inhibitor 17-AAG effectively reduces multiple myeloma cell growth. This occurs through down-regulating the Wnt/β-catenin pathway and inhibiting HSP90 expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
  • Heat shock protein 90 (HSP90) is a molecular chaperone that plays a critical role in the stability and function of numerous client proteins involved in cancer cell growth and survival.
  • Targeting HSP90 is a promising therapeutic strategy in various cancers, including multiple myeloma.

Purpose of the Study:

  • To evaluate the anti-proliferative effects of the HSP90 inhibitor 17-AAG on multiple myeloma cells.
  • To elucidate the underlying molecular mechanisms by which 17-AAG exerts its effects, focusing on the Wnt/β-catenin signaling pathway and HSP90 expression.

Main Methods:

  • Multiple myeloma U266 cells were treated with varying concentrations of 17-AAG (200-800 nmol/L) for 24, 48, and 72 hours.
  • Cell proliferation was assessed using the MTT assay.
  • Protein expression levels of β-catenin and C-MYC were determined by Western blot, and cell cycle distribution was analyzed via flow cytometry.

Main Results:

  • 17-AAG demonstrated a significant dose- and time-dependent inhibition of U266 cell proliferation.
  • Treatment with 17-AAG led to a dose-dependent decrease in the expression of β-catenin and C-MYC proteins.
  • 17-AAG treatment resulted in an increased proportion of cells in the G1 phase of the cell cycle in a dose- and time-dependent manner.

Conclusions:

  • The HSP90 inhibitor 17-AAG exhibits potent anti-proliferative activity against multiple myeloma cells.
  • The observed effects are likely mediated by the down-regulation of the Wnt/β-catenin signaling pathway and the inhibition of HSP90 expression.
  • 17-AAG represents a potential therapeutic agent for multiple myeloma treatment.

More Related Videos

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.8K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K